Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wein

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Anticancer Research|March 16, 2004
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC)K Link, K Happich, I Schirner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Oncology|February 5, 2003
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancerA Wein, C Riedel, W Brückl, et al.
Anticancer Research|June 25, 2003
Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapyW M Brueckl, C Moesch, T Brabletz, et al.
Anticancer Research|February 19, 2002
Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patientsW M Brueckl, J M Preuss, A Wein, et al.
JAMA|September 28, 1998
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapyA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trialsA V D'Amico, R Whittington, S B Malkowicz, et al.
Cancer|May 20, 1998
Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapyA V D'Amico, A Desjardin, A Chung, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Anticancer Research|March 16, 2004
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC)K Link, K Happich, I Schirner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Oncology|February 5, 2003
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancerA Wein, C Riedel, W Brückl, et al.
Anticancer Research|June 25, 2003
Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapyW M Brueckl, C Moesch, T Brabletz, et al.
Anticancer Research|February 19, 2002
Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patientsW M Brueckl, J M Preuss, A Wein, et al.
JAMA|September 28, 1998
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapyA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancerA V D'Amico, R Whittington, S B Malkowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trialsA V D'Amico, R Whittington, S B Malkowicz, et al.
Cancer|May 20, 1998
Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapyA V D'Amico, A Desjardin, A Chung, et al.
Pageof 11